ELCC 2024 | PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLC

Joshua Sabari, NYU Langone Health in New York, NY, discusses the patient-reported outcomes (PROs) of the Phase III PAPILLON (NCT04538664) trial, which assessed amivantamab plus chemotherapy versus chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC). The primary outcome of the trial revealed a 33% reduction in the risk of symptomatic progression or death in patients receiving amivantamab plus chemotherapy compared to chemotherapy alone, with a hazard ratio (HR) of 0.67. Significant improvements were observed in patient-reported key symptoms at both 6 and 12 months using the The EORTC QLG Core Questionnaire (EORTC QLQ-C30). Additionally, the time to sustained deterioration in physical functioning was prolonged in the combination therapy arm, with a hazard ratio of 0.65. These findings complement the previously reported progression-free survival (PFS) data and response rates, further supporting the use of amivantamab plus chemotherapy in the frontline treatment of EGFR exon 20 mutant NSCLC. This interview took place at the ELCC 2024 meeting in Prague, Czech Republic.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.